Project Grant R33HL187274
Award Date 8/15/26
Completion Date 4/30/28
Dollars Obligated $509K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $165,888 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the genetic architecture of heart failure with preserved ejection fraction (HFPEF) and identify novel therapeutic targets. The recipient will enhance a machine learning model trained to predict HFPEF by incorporating cardiac MRIs and electrocardiograms, improving model specificity for genomic...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,912 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease. The research integrates artificial intelligence with genome engineering to discover intrinsic gene regulatory networks governing heart development. Stanford will employ a base-resolution neural network...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Stanford University a Project Grant of $159,512 under the Cardiovascular Diseases Research program (CFDA 93.837) effective December 1, 2025, with completion targeted for May 1, 2026. This grant supports research into amelioration of cardiac fibrosis using diverse cell village human cardiac organoids. The project focuses on developing and validating therapeutic approaches to combat fibroblast activation, a...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $769,846 on July 1, 2026, under Cardiovascular Diseases Research (CFDA 93.837), a Project Grant assistance type. The recipient will develop and apply an integrative genomics toolkit to characterize and engineer edits to regulatory DNA sequences with the goal of reprogramming gene expression for therapeutic applications. The toolkit combines computational models to predict how sequence changes to enhancers...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $2,339,136 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of phospholamban in regulating perinuclear calcium signaling and pathological cardiac gene expression as a potential therapeutic target for dilated cardiomyopathy. The funded research examines how phospholamban interacts with the scaffold protein AKAP6B at the myocyte outer nuclear...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $1,541,206 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify druggable targets for cancer therapy-induced cardiotoxicity. The research characterizes proteasome inhibitor-induced cardiovascular toxicity through three aims. Aim 1 profiles cell type-specific cytotoxicity using patient-specific induced pluripotent stem cell-derived cardiomyocytes and endothelial...